Shares in Astrazeneca cracked in Wednesday's (September 9, 2020) trade extending previous day's over 8% losses and lost 12% today.
This is after the pharma player was making consecutive gains but now the gains have been washed away as the likely Covid 19 vacccine candidate's last trial which was being worked upon in association with Oxford University has been stalled as there was seen an adverse reaction in one of the participant in the United Kingdom.
The company is now investigating if a report of a patient with a serious side effect is linked to the shot.
"Standard review process triggered a pause to vaccination to allow review of safety data", the company said in a statement on September 8, 2020.
The AstraZeneca-Oxford vaccine is viewed as the most effective vaccine against the deadly infection.